Aspirin and dipyridamole in the prevention of restenosis after percutaneous transluminal coronary angioplasty.

To examine the role of antiplatelet therapy in the prevention of arterial restenosis after percutaneous transluminal coronary angioplasty (PTCA), we conducted a randomized, double-blind, placebo-controlled study in 376 patients. The active treatment consisted of an oral aspirin-dipyridamole combination (330 mg-75 mg) given three times daily, beginning 24 hours before PTCA. Eight hours before PTCA, the oral dipyridamole was replaced with intravenous dipyridamole at a dosage of 10 mg per hour for 24 hours, and oral aspirin was continued. Sixteen hours after PTCA, the initial combination was reinstituted. Treatment was continued in patients with a successfully dilated vessel until follow-up angiography four to seven months after PTCA--or earlier, if symptoms dictated. Of 249 patients who underwent follow-up angiography, 37.7 percent of patients receiving the active drug had restenosis in at least one segment, as compared with 38.6 percent of patients taking placebo (P not significant). The number of stenotic segments was virtually the same in the two groups. Among the 376 randomized patients, there were 16 periprocedural Q-wave myocardial infarctions--13 in the placebo group and 3 in the active-drug group (6.9 percent vs. 1.6 percent, P = 0.0113). Although the use of this antiplatelet regimen before and after PTCA did not reduce the six-month rate of restenosis after successful coronary angioplasty, it markedly reduced the incidence of transmural myocardial infarction during or soon after PTCA. Thus, the short-term use of antiplatelet agents in relation to PTCA can be recommended.

[1]  Lynne H. Taylor,et al.  Aspirin and dipyridamole in the prevention of acute coronary thrombosis complicating coronary angioplasty. , 1987, Circulation.

[2]  J. Douglas,et al.  Coumadin and aspirin in prevention of recurrence after transluminal coronary angioplasty: a randomized study. , 1984, Circulation.

[3]  J. Mehta Role of platelet antagonists in coronary artery disease: implications in coronary artery bypass surgery and balloon-catheter dilatation. , 1984, American heart journal.

[4]  B. Meier,et al.  Effect of nifedipine on recurrent stenosis after percutaneous transluminal coronary angioplasty. , 1986, Journal of the American College of Cardiology.

[5]  V. Fuster,et al.  Is vasospasm related to platelet deposition? Relationship in a porcine preparation of arterial injury in vivo. , 1987, Circulation.

[6]  M. Bourassa,et al.  Failure of diltiazem to prevent restenosis after percutaneous transluminal coronary angioplasty. , 1985, American heart journal.

[7]  P J de Feyter,et al.  Early detection of restenosis after successful percutaneous transluminal coronary angioplasty by exercise-redistribution thallium scintigraphy. , 1985, The American journal of cardiology.

[8]  D. Holmes,et al.  Efficacy of adjunctive dextran during percutaneous transluminal coronary angioplasty. , 1984, The American journal of cardiology.

[9]  J. J. Gerbrands,et al.  Coronary Artery Dimensions from Cineangiograms-Methodology and Validation of a Computer-Assisted Analysis Procedure , 1984, IEEE Transactions on Medical Imaging.

[10]  M. Bourassa,et al.  Clinical and angiographic assessment 6 months after double vessel percutaneous coronary angioplasty. , 1985, Journal of the American College of Cardiology.

[11]  V. Fuster,et al.  Balloon angioplasty. Natural history of the pathophysiological response to injury in a pig model. , 1985, Circulation research.

[12]  B Meier,et al.  Restenosis after successful coronary angioplasty in patients with single-vessel disease. , 1986, Circulation.

[13]  S Levine,et al.  Coronary angioplasty: clinical and angiographic follow-up. , 1985, The American journal of cardiology.

[14]  C Vallbracht,et al.  Recurrence rate after successful coronary angioplasty. , 1985, European heart journal.

[15]  V. Fuster,et al.  Effect of dipyridamole and aspirin on late vein-graft patency after coronary bypass operations. , 1984, The New England journal of medicine.

[16]  E. Simonson,et al.  The Electrocardiogram in Population Studies: A Classification System , 1960, Circulation.

[17]  T. Ryan,et al.  Platelet accumulation in experimental angioplasty: time course and relation to vascular injury. , 1987, Circulation.

[18]  V. Fuster,et al.  A platelet-inhibitor-drug trial in coronary-artery bypass operations: benefit of perioperative dipyridamole and aspirin therapy on early postoperative vein-graft patency. , 1982, The New England journal of medicine.

[19]  J. J. Gerbrands,et al.  Assessment of short-, medium-, and long-term variations in arterial dimensions from computer-assisted quantitation of coronary cineangiograms. , 1985, Circulation.

[20]  J. Oates,et al.  Drug therapy. Dipyrimadole , 1987 .

[21]  D. Faxon,et al.  Percutaneous transluminal coronary angioplasty in 1985-1986 and 1977-1981. The National Heart, Lung, and Blood Institute Registry. , 1988, The New England journal of medicine.

[22]  V. Fuster,et al.  Deep arterial injury during experimental angioplasty: relation to a positive indium-111-labeled platelet scintigram, quantitative platelet deposition and mural thrombosis. , 1986, Journal of the American College of Cardiology.

[23]  R E Vlietstra,et al.  Restenosis after percutaneous transluminal coronary angioplasty (PTCA): a report from the PTCA Registry of the National Heart, Lung, and Blood Institute. , 1984, The American journal of cardiology.

[24]  V. Fuster,et al.  Reduction of intimal thickening in canine coronary bypass vein grafts with dipyridamole and aspirin. , 1978, The American journal of cardiology.